Related Experiment Video
Updated: Apr 23, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting HER2 in ovarian and uterine cancers: challenges and future directions
Eleonora Teplinsky1, Franco Muggia1
1New York University Cancer Institute, 160 East 34th Street, New York, NY 10016, USA.
Abstract:
Targeting the human epidermal growth factor receptor 2 (HER2) has yielded major advances in breast cancer treatment. Accordingly, it has generated interest in targeting HER2 to treat gynecologic malignancies. Multiple studies have evaluated the rates of HER2 overexpression and/or amplification in ovarian and uterine cancers. HER2 has also been studied as a prognostic factor but resulting data has been contradictory. Moreover, clinical trials of HER2-directed therapies, including trastuzumab, pertuzumab, and lapatinib in ovarian and uterine cancers have been largely disappointing. Current research on HER2 in gynecologic malignancies has focused on identifying mechanisms of resistance and looking further into how HER2 signaling in gynecologic cancers differs from breast cancer. In this review, we highlight the existing data of targeting HER2 in ovarian and uterine carcinomas, many dating back more than a decade, and discuss future directions in pursuing HER2 as a potential target in these diseases.
Insights
Targeting human epidermal growth factor receptor 2 (HER2) shows promise in gynecologic cancers, but clinical trials with HER2-directed therapies have been disappointing. Future research focuses on resistance mechanisms and HER2 signaling differences compared to breast cancer.
Area of Science:
- Oncology
- Gynecologic Oncology
- Molecular Biology
Background:
- Human epidermal growth factor receptor 2 (HER2) targeting revolutionized breast cancer treatment.
- This success spurred interest in HER2 as a therapeutic target for gynecologic malignancies, including ovarian and uterine cancers.
Purpose of the Study:
- To review existing data on HER2 targeting in ovarian and uterine carcinomas.
- To discuss future research directions for HER2 as a potential therapeutic target in these cancers.
Main Methods:
- Review of published literature on HER2 expression, amplification, and clinical trials in ovarian and uterine cancers.
- Analysis of HER2 signaling pathways and resistance mechanisms in gynecologic malignancies.
Main Results:
- HER2 overexpression/amplification rates in ovarian and uterine cancers have been evaluated, with contradictory findings regarding its prognostic value.
- Clinical trials of HER2-directed therapies (trastuzumab, pertuzumab, lapatinib) in these cancers have yielded largely disappointing results.
Conclusions:
- Despite initial promise, HER2-directed therapies have shown limited efficacy in ovarian and uterine cancers.
- Further research is needed to understand HER2 signaling and resistance mechanisms to identify effective strategies for HER2 targeting in gynecologic malignancies.
More Related Videos
14:25Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 20, 2014
07:54Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle